Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- NewAmsterdam Pharma
- Study ID
- NCT05142722
- Phase
- PHASE3
- Status
- Completed
Conditions
- Atherosclerotic Cardiovascular Disease
- Dyslipidemias
- Familial Hypercholesterolemia
- High Cholesterol
- Hypercholesterolemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGplacebo tablet made to resemble active
- Obicetrapib — DRUG10mg obicetrapib tablet
Study Details
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
Key Dates
- Start date
- Dec 15, 2021
- Status verified
- Feb 2025
- Primary completion
- Sep 26, 2024
- Completion
- Sep 26, 2024
Study Design
- Enrollment
- 2,530 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placeboone placebo tablet once daily
- Experimental: obicetrapib 10mgone 10mg obicetrapib tablet once daily
Primary Outcome Measure
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] [ Time Frame: 84 Days ]
Locations (69)
Related coverage on Hipa.ai
- Obicetrapib Phase 3 Trial Reduces LDL-C by 29.94% in DyslipidemiaObicetrapib · Sep 19, 2025 · ClinicalTrials.gov
Find similar trials in Anniston, AL
By research site
Pinnacle Research Group· Anniston, ALCentral Alabama Research· Birmingham, ALSynexus Clinical Research US, Inc. / Simon Williamson Clinic, PC· Birmingham, ALThe Center for Clinical Trials, Inc· Saraland, ALSyed Research Consultants, LLC· Sheffield, ALClinical Research Institute of Arizona, LLC· Sun City West, AZ
Related Studies
- Causes and Natural History of DyslipidemiasRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Alirocumab in Patients on a Stable Dialysis RegimenPHASE3 · Recruiting · Baylor Research Institute · Dallas, Texas
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionPHASE3 · Enrolling By Invitation · LIB Therapeutics LLC · Evanston, Illinois
- 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)PHASE2 · Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee